Core Viewpoint - Ascentage Pharma Group International will release its full year 2025 unaudited results and provide business updates on March 25, 2026, at 7:00 pm EDT [1] Group 1: Upcoming Events - Analysts and investors are invited to join an investor webcast with Q&A conducted by the company's management team, scheduled for March 25, 2026, at 10:00 pm EDT [2] - An English language investor webcast will be held on March 26, 2026, at 8:00 am EDT, with a replay available on the company's website [3] Group 2: Company Overview - Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for unmet medical needs in cancer [4] - The company has developed a rich pipeline of innovative drug products, including inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [4] Group 3: Approved Products - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for treating chronic myeloid leukemia (CML) with specific mutations and is included in China's National Reimbursement Drug List [5] - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for various hematologic malignancies and has been approved for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have received prior systemic therapy [6] Group 4: Research and Development - Ascentage Pharma has established a portfolio of global intellectual property rights and formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer [7]
Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026